FDA has approved AstraZenecaâ€™s Movantik for opioid-induced constipation in adults with chronic non-cancer pain. Movantik…
To date, only eleven PEGylated proteins, antibody fragments, oligonucleotides, and small molecules that have been approved by the FDA are on the market.
Available PEGylated Drugs
This includes PEGylated bovine adenosine deaminase: pegademase bovine (Adagen); and PEGylated l-asparaginase: pegaspargase (Oncaspar); PEGylated products of interferon-alpha (IFN-alpha): peginterferon-2b (PegIntron) and peginterferon-2a (Pegasys); PEGylated granulocyte colony stimulating factor (GCSF): pegfilgrastim (Neulasta); PEGylated growth hormone receptor antagonist: pegvisomant (Somavert); PEGylated a 28-nucleotide aptamer against vascular endothelial growth factor (VEGF); Pegaptanib sodium (Macugen); continuous erythropoietin receptor activator Mono-mPEG-epoetin- (Mircera); PEGylated Fab fragment of the humanized anti-tumor necrosis factor (TNF)-alpha monoclonal antibody certolizumab pegol (Cimzia); PEGylated recombinant porcine uricase (urate oxidase) (Puricase); and pegylated naloxol (naloxegol) (Movantik).
Current Drug Research on PEGylation with Small Molecule Agents, Progress in Polymer Science, 2013, 38, 421-444